|
|
Article: Current Research on Neurocrine Biosciences Inc.
- Article from:
- M2 Presswire
- Article date:
- November 7, 2006
CopyrightCOPYRIGHT 2006 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-7 November 2006-Biotech News: Current Research on Neurocrine Biosciences Inc.(C)1994-2006 M2 COMMUNICATIONS LTD
RDATE:07112006
Current Research on Neurocrine Biosciences Inc. (NASDAQ: NBIX)
For Neurocrine Biosciences, it's all chemical. The development-stage biotech develops treatments for diseases of the central nervous and immune systems. It bases its research on the molecular relationships among the body's central nervous, immune, and endocrine systems. Lead drug candidate Indiplon aims to treat insomnia; the company acquired rights to Indiplon from DOV Pharmaceutical. Neurocrine Biosciences is also developing treatments for anxiety, depression, ...